Biotech Values

[genisi]

This will be a crowded market, but a new MoA gives Vedolizumab a chance t be at least a medium-sized drug.

The MoA is not entirely new. However, vedolizumab is a selective and specific anti alpha 4 integrin chain mAb and unlike Tysabri that binds and inhibits other integrin, is not expected to have systemic immunosuppression effect.